

**AMENDMENTS TO THE SPECIFICATION:**

Please replace the paragraph beginning on page 15, line 8 with the following rewritten paragraph:

In a method of the present invention, the cells expressing BMP receptors are applied in the desired site as described above, and BMP is applied. The BMP may be applied simultaneously or immediately following application of the cells expressing BMP receptors. BMPs are known and have been described as follows: BMP-2 (sometimes referred to as BMP-2A) and BMP-4 (sometimes referred to as BMP-2B), U.S. Patent No. 5,013,649; BMP-3, U.S. Patent No. 5,116,738; BMP-5, U.S. Patent No. 5,106,748; BMP-6, U.S. Patent No. 5,187,076; BMP-7, U.S. Patent No. 5,141,905; BMP-8, PCT Publication No. WO93/00432; BMP-9, Serial No. 07/720,590, filed on June 25, 1991; BMP-10, Serial No. 08/061,695 [[\_\_\_\_\_]], filed on May 12, 1993. Heterodimers are described in United States Patent Application Serial No. 07/787,496, filed on April 7, 1992. The disclosure of the above references are hereby incorporated herein by reference as if fully reproduced herein. The BMP may be applied in manners known in the art, such as described in the above patents, as well as in United States Patent 5,171,579, the disclosure of which is also hereby incorporated by reference.

Please replace the paragraph on page 27, lines 28-29 with the following new paragraph:

1. Asn-Glu-Tyr-Val-Ala-Val-Lys (SEQ ID NO: 18)
2. His-Arg-Asp-Ile-Lys-Ser (SEQ ID NO: 19)

Please replace the paragraph on page 28, line 2 with the following new paragraph:

Oligonucleotide primer A: CGGGATCCGARTAYGTNGCNGTNAAR (SEQ ID NO:20)

Please replace the paragraph on page 28, lines 8-11 with the following new paragraph:

Oligonucleotide primer B: GACTCTAGARCTYTTDATRTCYCTRG (SEQ ID NO:21)

Oligonucleotide primer C: GACTCTAGARCTYTTDATRTCNCGRTG (SEQ ID NO:22)

Oligonucleotide primer D: GACTCTAGANGAYTTDATRTCYCTRG (SEQ ID NO:23)

Oligonucleotide primer E: GACTCTAGANGAYTTDATRTCNCGRTG (SEQ ID NO:24)

Please replace the paragraph beginning at page 34, line 26 with the following new paragraph:

The nucleotide sequence of clone CFK1-23a (deposited under the Budapest Treaty on August 3, 1993, at the American Type Tissue Collection, 10801 University Boulevard, Manassas, VA, 20110-2209, as accession [[ATCC]] # 69378) comprises an open reading frame of 1596 bp, encoding a CFK1-23a receptor protein of 532 amino acids. The encoded 532 amino acid CFK1-23a receptor protein is contemplated to be the primary translation product. The coding sequence is preceded by 60 bp of 5'

PATENT  
Customer No. 22,852  
Attorney Docket No. 08702.0048-03000

untranslated sequence. The DNA and derived amino acid sequence of the majority of the insert of CFK1-23a is set forth in SEQ ID NO:1.